Partnering to diversify and strengthen our product pipeline

We plan to continue to partner with pharmaceutical companies to access additional development and commercial resources, expertise and non-dilutive funding to enable the advancement of a broader and more diverse pipeline.


We have an ongoing collaboration with Genentech focused on developing novel inhibitors of NaV1.7 for the treatment of pain. Genentech has completed a Phase 1 clinical trial for GDC-0310, which is an oral, selective NaV1.7 small-molecule inhibitor developed for the potential treatment of pain. We formed a second collaboration with Genentech in March 2014 for pain genetics, with a focus on rare phenotypes where individuals have an inability to perceive pain or where individuals have non-precipitated spontaneous severe pain.